Lerdelimumab (CAT-152, intended trade name Trabio) is a human monoclonal antibody and an immunosuppressive drug targeting TGF beta 2.

It was being developed to reduce scarring after glaucoma drainage surgery.

[1] Development was stopped in late 2005 after unsuccessful trial results for that condition.

[2] Immune activation: Dostarlimab Other: Ibalizumab This monoclonal antibody–related article is a stub.

You can help Wikipedia by expanding it.This antineoplastic or immunomodulatory drug article is a stub.